STOCK TITAN

AYTU BioPharma (AYTU) 10-K Filings

AYTU NASDAQ

Here are the 10-K annual reports from AYTU BioPharma, Inc. (AYTU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow AYTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AYTU filings page.

Rhea-AI Summary

AYTU BioPharma, Inc. (AYTU) is a CNS-focused pharmaceutical company that has repositioned around commercial-stage prescription products, led by EXXUA, an FDA-approved extended-release antidepressant for adult major depressive disorder. The company exited its Consumer Health business in fiscal 2025 and now operates as a single commercial segment.

In fiscal 2026 AYTU generated $57.6 million in net revenue, including $6.6 million from the successful launch of EXXUA, while its ADHD portfolio produced $45.8 million and its pediatric product Karbinal ER $5.1 million amid reduced promotion. The company reported a $14.3 million net loss and an accumulated deficit of $347.8 million, but is prioritizing operational efficiencies and higher-margin products to pursue positive operating cash flow.

AYTU’s capital structure includes a term loan and revolving credit facility under the Eclipse Agreement, both maturing in 2029, and a June 2025 equity raise that delivered $14.8 million in net proceeds to support EXXUA commercialization. Key risks include double‑digit revenue declines in ADHD and pediatric portfolios, high customer concentration, a Paragraph IV challenge to Adzenys, extensive regulatory and compliance obligations, and the possibility of Nasdaq delisting if listing standards are not maintained.

Rhea-AI Summary

Aytu BioPharma reported mixed 2025 results with strategic financing, asset impairments and a planned product launch. The company raised gross proceeds of $16.6 million in June 2025 through the sale of 2,806,688 common shares and 8,233,332 prefunded warrants; the prefunded warrants had an issuance fair value of approximately $12.3 million and $1.3 million of issuance costs were recorded in other (expense) income. In June 2025 the company recorded a $8.3 million impairment to product technology rights and also recognized a separate $2.7 million full impairment of other intangible assets. Aytu expects to launch EXXUA in the fourth calendar quarter of 2025 and capitalized commercialization rights with an estimated useful life through September 2030. Debt includes an amended Eclipse credit facility with $9.1 million outstanding on the revolving loan and an amended term loan (effective interest ~11.4%) after a $13.0 million increase; the company has a $100.0 million shelf registration with $100.0 million remaining available. The Consumer Health business was divested and is reported as discontinued operations.